Fate Therapeutics Inc. buy marge
Start price
27.06.19
/
50%
€17.84
Target price
04.11.21
€82.00
Performance (%)
183.83%
End price
05.11.21
€50.64
Summary
This prediction ended on 05.11.21 with a price of €50.64. With a performance of 183.83% the BUY prediction by marge was a big success. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Fate Therapeutics Inc. | 16.840% | 16.840% | -16.044% | -79.824% |
| iShares Core DAX® | 1.432% | 2.628% | 12.457% | 60.347% |
| iShares Nasdaq 100 | 1.892% | -0.458% | 1.248% | 85.806% |
| iShares Nikkei 225® | -1.619% | 11.097% | 27.382% | 64.398% |
| iShares S&P 500 | 1.921% | 1.159% | 1.635% | 59.419% |
Comments by marge for this prediction
In the thread Fate Therapeutics Inc. diskutieren
marge stimmt der Buy-Einschätzung der Analysten zu
Piper Jaffray is reissuing its Buy rating on Fate Therapeutics (FATE) today, but lifting its price target seven bucks a share to $30. Piper's analyst states 'the company remains a top pick for the second half of 2019 given its "first-in-class iPSC cancer cell pipeline'.
Kursziel geändert auf 32,0
Kursziel geändert auf 82,0
In the thread Trading Fate Therapeutics Inc.
Die von marge gewählte maximale Laufzeit wurde überschritten